Organigram CEO warns of unsustainably cheap cannabis, reports CA$7.5M quarterly loss

April 13, 2023 · MJ Biz Daily

The CEO of Canadian producer Organigram Holdings is warning about heavily discounted marijuana in the nation’s recreational market, saying that ultra-low prices are “not sustainable and (hurt) the cannabis industry.”

The company’s chief executive, Beena Goldenberg, said on a Wednesday quarterly earnings call that, although “many producers have discussed not wanting to participate in a race to the bottom, we are seeing the opposite in the market.”

Goldenberg said large, 28-gram cannabis flower packages retailing for less than 100 Canadian dollars (roughly $75) have “increased by almost 300% over the past six months.”

“Large-format pricing in some markets has reached the point that, considering the cost of production and the excise tax burden, the products are being sold at a loss.”

Goldenberg added that Organigram’s “low-cost structure allows us to compete at these reduced prices” but said the Toronto-based company has “not matched the aggressiveness of our competitors and have seen some market share erosion in our large-format flower.”

Later in the call, Goldenberg said Organigram would continue competing in the large-format flower segment, “but we just won’t compete at the very low prices, it’s just not sustainable.”

The cannabis executive’s comments came as Organigram reported a net loss of CA$7.5 million for the quarter ended Feb. 28, as net revenue grew 24% from the same quarter last year to CA$39.5 million.

The company’s net loss increased 85% compared to the second quarter of 2022, with Organigram attributing that increased net loss to “to the change in fair value of derivative warrant liabilities.”

In its previous quarter, Organigram reported a net profit of CA$5.3 million.

Goldenberg said the second quarter is typically Organigram’s lowest for sales due to seasonality, with sales peaking during the summertime fourth quarter.

Organigram’s chief financial officer, Derrick West, said on the call that Organigram expects “to generate positive free cash flow by the end of calendar (year) 2023.”

Organigram claimed the No. 3 spot among licensed Canadian cannabis producers, with leading positions in pre-ground flower and hashish and a third-place spot in gummies.

CEO Goldenberg said Organigram is “underdeveloped” in the vape segment compared to its competitors.

However, she expressed optimism that Organigram’s recent CA$4 million investment in vape hardware company Greentank – which comes with an exclusivity period for Organigram to use the Toronto-headquartered businesses’ upcoming technology in Canada – will help differentiate her company’s vape products in the future.

Goldenberg said the pending vape hardware “doesn’t have the partially cooked oil that saturates the old ceramic coils, that causes the clogging and leaks and the unpleasant flavor.”

Meanwhile, Organigram is fighting back against a regulatory decision that puts another product segment at risk.

Health Canada recently asked Organigram to stop selling its Edison Jolts cannabis lozenges, which contain 100 milligrams of THC per package, over concerns that the products are misclassified as cannabis extracts rather than edibles.

Goldenberg said Organigram can keep selling the products through May 31 and “(remains) of the view that the patent-pending Jolts are properly classified as cannabis extracts and compliant with cannabis regulations.”

She said Organigram has “filed an application with the Federal Court of Canada seeking judicial review of Health Canada’s determination.”

“As court proceedings can take some time, we intend to file a motion for a stay, seeking to set aside the decision in the interim.” (Full Story)

In category:International
Next Post

Germany Scales Back Its Cannabis Legalization Plan

German officials have announced they are scaling back their widely anticipated cannabis legalization plan following a discussion with European Union officials, the Associated Press reports. The new plan, revealed on Wednesday, is to legalize cannabis possession of up to 25 grams and establish nonprofit…
Previous Post

Canadian cannabis producer Phoena winds-down business, blames high taxes

Canadian cannabis producer Phoena Group has been granted creditor protection and is winding down its operations, the company said in court documents. The Vaughan, Ontario-based company – formerly called CannTrust – said it no longer has the financial footing to…
Random Post

The rebirth of psychedelic medicine

It was 1985 and John Lawn had seen enough.  In Boston nightclubs and Dallas bars, MDMA — better known by its street name, ecstasy — had become an enormously popular recreational drug. It had also terrified the Reagan administration, which…
Random Post

TerrAscend Steps Closer To The TSX

TerrAscend Corp. (CSE: TER) (OTC: TRSSF) decided to celebrate 420 by filing its preliminary proxy statement with the U.S. Securities and Exchange Commission in its next step to listing on the Toronto Stock Exchange (the TSX). While the company had hoped to…
Random Post

Kansas Senators Shelve Medical Marijuana Legalization Bill After Hearing From Law Enforcement Opponents

Kansas senators have shelved a bill to legalize medical marijuana following a hearing that featured multiple opponents, including state law enforcement representatives. Members of the Senate Federal and State Affairs Committee voted on Thursday to table the legislation, which the panel itself…
Random Post

Federal Judge Allows Lawsuit About Religious Use of Hallucinogenic Tea to Move Forward

Parties exchanged legal barbs over religious freedom and the Controlled Substances Act. A U.S. federal judge ruled that a lawsuit by an Arizona religious group seeking legal approval to use a hallucinogenic tea in its rituals can proceed. The Arizona…